knowledge -WSS

knowledge

author：focus 2025-09-30 21:40:00 - browse：47363

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Let's speed up science by embracing open access publishing

entertainment

WSS

NIH documents show early flaws of $1.6 billion long Covid program

Is it ever OK for doctors to lie to their patients?

Ionis drug prevents swelling attacks due to hereditary angioedema

Has Bernie Sanders reached the limit of his pharma bullying effort?

Woman returns to dialysis after doctors remove transplanted pig kidney

GSK’s asthma push continues as drug succeeds in Phase 3 trials

knowledge

knowledge

explore

Medicare proposal to cover medical devices draws a mixed reaction

Lawmakers grill UnitedHealth CEO on Change cyberattack

Activists slam private health insurers over coverage restrictions

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

DIEP, the 'gold standard' of breast reconstruction, is under threat

Warren pushes Witty on UnitedHealth's control over physicians

Walensky prepares to leave CDC — and Congress — behind

Ultragenyx gene therapy for rare liver ailment succeeds in late

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Brain MRIs reveal impact of 'toxic stress' on Black children

explore

Chemotherapy before breast cancer surgery might fuel metastasis

Brain technologies pose threats that are all too real, experts warn

Kaiser's Risant Health gobbled up Geisinger. Who is next?

See how much Covid

BMI, flaws aside, is found to be useful estimate of body fat in youth

Welsh Carson private equity firm escapes from FTC antitrust case

knowledge

focus

entertainment

focus